SHENZHEN, China, Jan. 14 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com management representatives are currently in China negotiating a merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope).
Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.
Mellow Hope revenues are currently in excess of $15 million USD, and growing.
Interim company CEO Keith Roberts noted "We think there are going to be strong synergies between our European division and Mellow Hope. Mellow Hope brings a substantial pharmaceutical production and testing capability to the forefront of the Company. In turn, HTDS can provide vital and meaningful assistance to Mellow Hope in developing its export business to Europe and beyond".
Based on initial negotiations, the company anticipates having a formal Letter of Intent in place within a week to ten days, and will provide additional updates on developments as they unfold.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment